Table 2. Factors Associated With Excess Survivorship Cost in Head and Neck Cancer, 2006 to 2018.
| Factors | Excess survivorship cost, estimate (95% CI), $/moa | |
|---|---|---|
| Total cost | Out-of-pocket cost | |
| Male sex | 0 [Reference] | 0 [Reference] |
| Female sex | 318.2 (98.9 to 537.5) | 9.6 (4.2 to 15.0) |
| Age group, y | ||
| ≥60 | 0 [Reference] | 0 [Reference] |
| <40 | 118.1 (−340.9 to 577.2) | −7.3 (−18.6 to 4.0) |
| 40-44 | −394.0 (−832.2 to 44.1) | −19.9 (−30.7 to −9.1) |
| 45-49 | −243.7 (−581.9 to 94.5) | −5.5 (−13.9 to 2.8) |
| 50-54 | −434.4 (−713.6 to −155.3) | −6.3 (−13.2 to 0.6) |
| 55-59 | −218.3 (−467.2 to 30.5) | −5.4 (−11.6 to 0.7) |
| Employment status | ||
| Active | 0 [Reference] | 0 [Reference] |
| Other/unknown | 21.8 (−181.9 to 225.5) | 11.7 (6.7 to 16.7) |
| Retiree | 37.4 (−275.7 to 350.5) | −8.0 (−15.8 to −0.3) |
| Health plan type | ||
| PPO | 0 [Reference] | 0 [Reference] |
| CDHP/HDHP | −456.3 (−767.2 to −145.5) | 18.1 (10.4 to 25.7) |
| Comprehensive | −63.9 (−537.5 to 409.6) | −14.6 (−26.3 to −2.9) |
| EPO/missing | 507.6 (−33.4 to 1048.7) | −27.7 (−41.1 to −14.4) |
| HMO/POS | −151.0 (−385 to 83.1) | −39.4 (−45.2 to −33.6) |
| Region | ||
| Northeast | 0 [Reference] | 0 [Reference] |
| North Central | 52.0 (−242.5 to 346.6) | 18.4 (11.1 to 25.7) |
| South | −149.6 (−415.8 to 116.7) | 36.9 (30.3 to 43.4) |
| West | −74.4 (−397.6 to 248.8) | 19.5 (11.6 to 27.5) |
| Unknown | −2244.3 (−10 892.5 to 6403.9) | −35.4 (−248.6 to 177.8) |
| Residence | ||
| Rural | 0 [Reference] | 0 [Reference] |
| Urban | −133.3 (−387.6 to 121.0) | −8.8 (−15.0 to −2.5) |
| Cancer site | ||
| Oral cavity | 0 [Reference] | 0 [Reference] |
| Hypopharynx | 1991.8 (1180.6 to 2802.9) | 21.7 (1.7 to 41.7) |
| Larynx | 227.7 (−118.5 to 573.8) | −3.2 (−11.7 to 5.3) |
| Multiple sites | −71.4 (−440.8 to 297.9) | 0.1 (−9.0 to 9.2) |
| Nasopharynx | 192.2 (−333.5 to 717.8) | 10.3 (−2.6 to 23.3) |
| Oropharynx | −718.0 (−984.7 to −451.4) | −13.6 (−20.2 to −7.1) |
| Other site | 0.4 (−348.6 to 349.5) | 3.4 (−5.2 to 12.0) |
| Salivary | −537.4 (−927.4 to −147.5) | −20.6 (−30.2 to −11.0) |
| Sinonasal | 1116.0 (586.0 to 1645.9) | 13.7 (0.7 to 26.8) |
| Treatment course | ||
| RT and CT | 0 [Reference] | 0 [Reference] |
| CT only | 796.3 (132.4 to 1460.3) | −11.7 (−28.0 to 4.7) |
| RT only | −1558.1 (−1841.5 to −1274.8) | −22.0 (−29 to −15.1) |
| Surgery only | −1954.5 (−2241.4 to −1667.5) | −38.1 (−45.1 to −31.0) |
| Surgery and CT | 2853.3 (1646.0 to 4060.6) | 44.7 (14.9 to 74.4) |
| Surgery and RT | −703.8 (−1010.5 to −397.1) | −8.4 (−15.9 to −0.8) |
| Surgery, CT, and RT | 2333.6 (2041.0 to 2626.2) | 25.5 (18.3 to 32.7) |
Abbreviations: CDHP, consumer-driven health plan; CT, chemotherapy; EPO, exclusive provider organization; HDHP, high deductible health plan; HMO, health maintenance organization; POS, point of service; PPO, preferred provider organization; RT, radiation therapy.
a
Models are adjusted for all variables listed and each Elixhauser comorbidity variable.